Journal
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
Volume 10, Issue 1, Pages 115-123Publisher
JOHN WILEY & SONS LTD
DOI: 10.1002/ueg2.12176
Keywords
chronic hepatitis B; clinical management; nucleos(t)ide analogues; screening; treatment discontinuation
Categories
Funding
- Fonds Wetenschappelijk Onderzoek [18B2821N]
Ask authors/readers for more resources
Chronic hepatitis B affects over 250 million people globally with increased risks of liver-related complications, yet many remain asymptomatic. NA therapy has shown excellent clinical outcomes, but the need for reliable biomarkers to identify patients suitable for treatment withdrawal is urgent. Renewed approaches to screening and linkage to care are essential for optimizing clinical management of chronic hepatitis B.
Worldwide, over 250 million people are chronically infected with the hepatitis B virus (HBV). Infected patients have an up to 100-fold increased risk for liver-related complications, including cirrhosis, hepatic decompensation and hepatocellular carcinoma. Nonetheless, the majority of the infections remains asymptomatic, stressing the importance of HBV screening and linkage to care. Excellent clinical outcomes are seen during nucleos(t)ide analogue (NA) therapy, which often is continued indefinitively due to a lack of functional cure. Increasing evidence suggests that NA discontinuation following long-term treatment induced viral suppression in patients without a functional cure may be a favourable option. Reliable biomarkers are, however, urgently needed to select the patients that would benefit from NA withdrawal. In addition, renewed and novel approaches to improve screening and linkage to care are other fundamental factors in the optimisation of the clinical management of chronic hepatitis B.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available